Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174286
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mallandrich Miret, Mireia | - |
dc.contributor.author | Calpena Campmany, Ana Cristina | - |
dc.contributor.author | Clares Naveros, Beatriz | - |
dc.contributor.author | Parra Coca, Alexander | - |
dc.contributor.author | García López, María Luisa | - |
dc.contributor.author | Soriano-Ruiz, José L. | - |
dc.contributor.author | Francisco Fernández-Campos | - |
dc.date.accessioned | 2021-02-25T07:02:53Z | - |
dc.date.available | 2022-02-15T06:10:19Z | - |
dc.date.issued | 2021-02-15 | - |
dc.identifier.issn | 1743-5889 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174286 | - |
dc.description.abstract | Aim: The development and optimization of Ketorolac tromethamine-loaded polylactic-co-glycolic acid nanoparticles (KT-NPs) for the treatment of inflammatory processes of the eye. Materials & methods: KT-NPs were developed by factorial design and characterized by assessing their physicochemical properties. Biopharmaceutical behavior studies, ocular tolerance, anti-inflammatory efficacy and bioavailability tests were performed on pigs. Results: Optimized KT-NPs of 112 nm, narrow distribution with encapsulation efficiency near 100% were obtained. KT release followed the Weibull model and there was significantly greater retention in the cornea and sclera than in the commercial reference. KT-NPs showed no signs of ocular irritancy and similar anti-inflammatory efficacy to the commercial reference. Conclusion: KT-NPs were a suitable alternative for the treatment of inflammatory disorders of the anterior and posterior segments of the eye as an alternative to conventional topical formulations. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Future Medicine | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.2217/nnm-2020-0403 | - |
dc.relation.ispartof | Nanomedicine, 2021, vol. 13, num. 3 | - |
dc.relation.uri | https://doi.org/10.2217/nnm-2020-0403 | - |
dc.rights | (c) Future Medicine, 2021 | - |
dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | - |
dc.subject.classification | Oftàlmia | - |
dc.subject.classification | Agents antiinflamatoris | - |
dc.subject.classification | Nanopartícules | - |
dc.subject.classification | Administració de medicaments | - |
dc.subject.other | Ophthalmia | - |
dc.subject.other | Antiinflammatory agents | - |
dc.subject.other | Nanoparticles | - |
dc.subject.other | Administration of drugs | - |
dc.title | Nano-engineering of ketorolac tromethamine platforms for ocular treatment of inflammatory disorders | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 707250 | - |
dc.date.updated | 2021-02-25T07:02:53Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
707250.pdf | 651.8 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.